Gabatarwa:Barka da zuwa shafin yanar gizon MOL Changes.ltd! A cikin wannan labarin, ƙwararrun peptide MDs za su ba ku cikakken jagora kan yadda za a sake dawo da Tirzepatide foda, magani don ciwon sukari da asarar nauyi[1][5]. Ko kai kwararre ne na kiwon lafiya, ko mara lafiya, fahimtar yadda za a sake dawo da Tirzepatide peptide daidai yana da mahimmanci don samun mafi kyawun Tirzepatide..
Menene Tirzepatide Peptide?
Tirzepatide shine glucagon-kamar peptide-1 (GLP-1) agonist mai karɓa. A cikin danyen sigar sa a matsayin foda, ana gudanar da shi ta hanyar subcutaneously don magance nau'in 2 ciwon sukari [1][2][4]da kiba[3]. Fahimtar yadda za a sake dawo da Tirzepatide foda daidai yana da mahimmanci ga nau'in 2 ciwon sukari da kiba.
Menene tsarin aikin Tirzepatide?
Tirzepatide peptide ne mai dual agonist na masu karɓar hormone da aka sani da GIP (Canje-canje na insulinotropic MOL masu dogaro da glucose) da GLP-1 (glucagon-kamar peptide-1). Wadannan hormones ana samar da su ta dabi'a a cikin jiki kuma suna taka muhimmiyar rawa wajen daidaita matakan sukari na jini da metabolism.
Yana ƙarfafa sakin insulin: Tirzepatide yana kunna masu karɓar GIP da masu karɓar GLP-1, duka biyun suna kan ƙwayoyin beta na pancreatic, ta haka yana kara kuzarin sakin insulin. Sakamakon kunna waɗannan masu karɓa, pancreas yana sakin insulin don amsa yawan sukarin jini. Insulin yana rage matakan sukari na jini saboda yana taimaka wa sel su sha glucose daga jini.
Yana hana sakin glucagon: Tirzepatide kuma yana hana sakin glucagon, wani hormone da pancreas ke samarwa. Glucagon yana haɓaka sukarin jini ta hanyar sa hanta ta saki glucose da aka adana. Tirzepatide yana dakatar da samar da glucose mai yawa ta hanyar rage sakin glucagon.
Ka'idojin cin abinci da zubar da ciki: A cikin sassan kwakwalwa da ke da hannu wajen daidaita tsarin ci, Hakanan ana samun masu karɓar GLP-1. Tirzepatide yana inganta satiety kuma yana rage cin abinci ta hanyar kunna waɗannan masu karɓa. Bugu da kari, GLP-1 yana sarrafa adadin abubuwan gina jiki, ciki har da glucose, Ana shiga cikin jini bayan cin abinci ta hanyar rage zubar da ciki.
Rage nauyi: Ayyukan agonist dual agonist na Tirzepatide a GIP da masu karɓa na GLP-1 suna da alaƙa da babban asarar nauyi.. Ta hanyar daidaita amfani da mai da kuma ƙara koshi, yana iya taimakawa rage yawan adadin kuzari da ƙara yawan kashe kuzari.
Tirzepatide yana aiki ta hanyar kunna masu karɓar GIP da GLP-1 don magance batutuwa daban-daban,gami da tsarin sarrafa sukarin jini, sakin insulin, rage glucagon, da kuma kula da ci.
Yadda za a RƘaddamar da Tirzepatide Foda?
Sake ginawa na Tirzepatide foda an raba shi da yawa matakai shida.
Mataki 1 Nemo rm yanayi
Nemo wuri mai tsabta da haske don shirya miyagun ƙwayoyi yayin da ake sake gina foda Tirzepatide. Tabbatar cewa saman ba shi da wani gurɓatawa.MOL Canje-canje
Mataki 2 Shirya nwajibi iabubuwa
Tirzepatide Foda
Ruwan bakararre don allura
Vial adaftar
sirinji
Mataki 3 Wtoka hannuwanku
Koyaushe wanke hannunka sosai da sabulu da ruwa kafin a sake dawo da foda na Tirzepatide don hana shigar da kwayoyin cuta ko wasu abubuwa masu cutarwa.
Mataki 4 Maimaita Tirzepatide podar
① Duba vial Tirzepatide peptide don kowane alamun lalacewa ko gurɓatawa. Kada a yi amfani idan vial ya karye ko foda ya canza launi;
② Cire hular kariyar daga vial mai ɗauke da foda Tirzepatide;
③ Shafa madaidaicin roba akan vial tare da swab na barasa don lalata;
④ Haɗa adaftar vial zuwa vial;
⑤ Bisa ga umarnin, Ɗauki sirinji kuma a zana ruwan da ya dace na bakararre don yin allura;
⑥ Sannu a hankali allura bakararre ruwa a cikin kwalbar Tirzepatide peptide. Jagorar rafin ruwa zuwa ɓangarorin vial don rage kumfa.
⑦ A hankali juya vial don haɗa ruwa da foda, kar a girgiza da karfi;
⑧ Bincika maganin da aka sake ginawa don kowane barbashi ko kumbura, a tabbatar an narkar da foda gaba daya kafin a ci gaba. Idan an sami wata matsala, kar a yi amfani da wannan maganin kuma ku watsar da shi yadda ya kamata.
Mataki 5 Fitar da maganin Tirzepatide gauraye
① Juya vial kuma saka sirinji a cikin adaftar vial;
② Sannu a hankali ja baya da plunger don fitar da adadin da ake buƙata na maganin Tirzeparatide;
③ Bincika sirinji don kumfa mai iska, idan akwai, danna sirinji a hankali don fitar dashi.
Mataki 6 Gudanarwa
Bayan cire maganin Tirzepatide, yi allura a daidai wurin allurar kamar yadda aka umarta.
Menene amfanin Tirzepatide peptide??
- Inganta asarar nauyi[3][6]. Ta hanyar hana ci, kara koshi, rage yawan adadin kuzari, don cimma asarar nauyi.
- Sarrafa da daidaita matakan sukari na jini[2][4]. Tirzepatide na iya sarrafawa da daidaita matakan sukari na jini ta hanyar daidaita GLP-1 da GIP (don rage glycated haemoglobin (HbA1c) matakan.
- Maganin cututtukan da ke da alaƙa da kiba. Tirzepatide na iya rage yawan cututtukan da ke da alaƙa da kiba yadda ya kamata (uku highs) da kuma kare tsarin zuciya da jijiyoyin jini.
- Dace. Tirzepatide yana buƙatar allurar sau ɗaya kawai a mako, wanda ke matukar saukaka rayuwar marasa lafiya.
- Hanyar gudanarwa tana da sassauƙa. Ana iya amfani da Tirzepatide kadai ko tare da wasu magungunan ciwon sukari don yin aiki mafi kyau.
Tasirin asarar nauyi mai ƙarfi yana sa Tirzepatide ya ba da shawarar ta hanyar ƙwararrun masana
Masana sun yarda cewa kiba-musamman kiba na ciki-abin haɗari ne mai zaman kansa ga ASCVD.. Rage nauyi ba kawai game da sarrafa nauyi ba ne, amma game da haɓaka abubuwan haɗari da yawa na ASCVD don rage cutar ASCVD da mace-mace. A halin yanzu ana rarraba magungunan antidiabetic zuwa cikin 4 azuzuwan dangane da tasirin asarar nauyi: mai karfi sosai, mai karfi, matsakaici kuma babu tasiri. Masana sun yarda cewa Tirzepatide da Semaglutide sune mafi tasiri magungunan hypoglycemic don asarar nauyi.. A gaskiya, jerin binciken SURPASS akan Tirzepatide sun nuna tasiri mai mahimmanci akan asarar nauyi.
Ƙungiyoyin kashi uku na Tirzepatide lyophilized foda (5 MG, 10 MG, 15 MG) ya nuna tasirin asarar nauyi fiye da duk ƙungiyoyin sarrafawa (gami da placebo ko magungunan sarrafa aiki) a cikin jerin karatun SURPASS, tare da asarar nauyi jere daga 6.5% ku 13.9%. Wannan binciken ya nuna cewa marasa lafiya tare da T2DM na iya amfani da magunguna masu mahimmanci don asarar nauyi na asibiti. Waɗannan magungunan suna da tasiri wajen rage haɗarin ASCVD. Bugu da kari, a cikin binciken SURPASS-AP-Combo na baya-bayan nan wanda ya shafi manya Sinawa masu ciwon sukari na T2, Rukunin kashi uku na Tirzepatide kuma sun nuna tasirin asarar nauyi (Tirzepatide ya rage ta 6.5% ku 9.4%; ƙungiyar kulawa ta karu ta 2.1%) , P < 0.05), wanda ke ba da shaidar shaidar likita don amfanin gaba. Ijma'in ƙwararru ya yi imanin cewa ASCVD yana da alaƙa da alaƙa da alamomin rayuwa da yawa (hawan jini, lipids na jini, sukarin jini, da dai sauransu.), sai dai kula da nauyi.
Ƙwararrun masana sun ba da shawarar cewa marasa lafiya marasa ciki su kiyaye HbA1c a ƙasa 7.0% don rage haɗarin ASCVD. Yana da game da asarar nauyi. A cikin jerin karatun SURPASS, duk rukunin kashi uku na Tirzepatide sun nuna babban tasirin hypoglycemic (rabon adadin 75% ku 97%, HbA1c da 7.0%).
MOL Yana Canza maganin rage nauyi Vs Maganin asarar nauyi na gargajiya
MOL na Gargajiya Canje-canje Tasirin
Wasu samfuran asarar nauyi na gargajiya suna da ɗan tasiri akan asarar nauyi (kamar Rimonaban);
Wasu daina amfani da su zai haifar da dawo da nauyi(kamar Sibutramine).
Tasirin yana da ban mamaki, kuma tasirinsa na asarar nauyi na iya kaiwa yawanci 10%-20%;
Ainihin ba za a sami dawowar nauyi ba bayan dakatar da amfani.
Tasirin illa Zai iya haifar da illa kamar ciwon daji, cututtukan zuciya da jijiyoyin jini, da kuma lalacewar jijiya.Kamar yadda magungunan halittu, Suna da ƙananan sakamako masu illa.Hanyar gudanarwa ana sha da baki kuma a sha kowace rana.Ta hanyar allura kuma yawanci sau ɗaya a mako[7]
Yadda ake adana Tirzepatide lyophilized foda?
Lyophilized foda form Tirzepatide ya kamata a adana a cikin firiji (tsakanin 2-8ºC). Ajiye tirzepatide a cikin kunshin asali har sai an yi amfani da shi don kariya daga haske. Alƙalami guda ɗaya (Tirzepatide ruwa allura) za a iya adanawa a dakin da zafin jiki don 21 kwanaki, idan ana bukata. Kar a daskare Tirzepatide. Daskarewa na iya yuwuwar lalata maganin kuma ya shafi tasirin sa. Ajiye magungunan ku kawai kamar yadda mai siyar da Tirzepatide ya umarta kamar MOL Changes.ltd. Tabbatar cewa kun fahimci yadda ake adana peptide ɗinku da kyau.
Tirzepatide foda sashi - Yadda ake amfani da Tirzepatide?
MOL Changes.ltd a matsayin mai siyar da Tirzepatide. Mu kawai muna da kyau wajen samar da Tirzepatide foda mai inganci. Tirzepatide foda sashi da bayanin gudanarwa da aka bayar a nan don dalilai ne kawai kuma bai kamata a yi la'akari da shi azaman shawarar likita ba.. Dosing na tirzepatide lyophilized foda zai iya bambanta dangane da yadda ake amfani da shi don nau'in 2 ciwon sukari da asarar nauyi. Bisa ga binciken da yawa, Anan ga janar tirzepatide jagorar sashi:
Maganin Tirzepatide don Nau'in 2 Ciwon sukari
Tirzepatide(Munjaro) Ana amfani da peptide azaman haɗin kai ga abinci da motsa jiki don haɓaka sarrafa glycemic a cikin manya tare da nau'in 2 ciwon sukari mellitus. Yawan allurai yana bin wannan tsari:
Kashi na farko: 2.5 MG subcutaneous allura sau ɗaya a mako don 4 makonni.
Adadin Kulawa: Ƙara zuwa 5 MG subcutaneous allura sau ɗaya a mako bayan farko 4 makonni.
Titration: Idan ana buƙatar ƙarin sarrafa glycemic, ana iya ƙara adadin a cikin 2.5 MG increments bayan akalla 4 makonni a kashi na yanzu.
Matsakaicin Kashi: Matsakaicin adadin shawarar shine 15 MG allurar subcutaneous sau ɗaya a mako.
Lura cewa farkon 2.5 MG kashi shine don farawa magani kuma ba shi da tasiri don sarrafa glycemic. Kuna buƙatar daidaita adadin ku bisa la'akari da amsa da bukatunku.
Maganin Tirzepatide don Rage Nauyi
Tirzepatide peptide an nuna don taimakawa wajen rasa nauyi a cikin marasa lafiya masu kiba. Dosing don asarar nauyi na iya bambanta kuma ana iya sanar da su ta gwajin gwaji kamar SURMOUNT-1 da SURMOUNT-2. MOL Changes.ltd kamar yadda Tizepatide foda mai sana'anta ba ya koyar da yadda ake amfani da Tirzepatide. Amma yuwuwar ƙa'idar asarar nauyi na iya zama:
Kashi na farko: 2.5 MG allurar subcutaneous sau ɗaya a mako don makonni huɗu na farko.
Ci gaba da haɓaka: Ƙara kashi zuwa 5 mg mako-mako a cikin makonni 5-8, 7.5 mg mako-mako a cikin makonni 9-12, kuma 10 mg mako-mako a cikin makonni 13-16.
Ƙarin Gyarawa: Dangane da amsawar mutum da haƙuri, la'akari da karuwa zuwa 12.5 mg mako-mako a cikin makonni 17-20, kuma har zuwa matsakaicin adadin 15 mg mako-mako daga mako 21 gaba.
Yawanci da Tsawon lokaci: Gudanar da allurar subcutaneous sau ɗaya a mako, kuma nazarin amfani da wannan ka'ida ya dade 24-72 makonni.
Yana da mahimmanci don tuntuɓar mai ba da lafiyar ku kafin yin kowane canje-canje ga adadin maganin ku. Wannan jagorar taƙaitaccen bayani ne kuma bai kamata ya maye gurbin shawarar likita na keɓaɓɓen ba. Mai ba da lafiyar ku zai ƙayyade tsarin da ya fi dacewa don ƙayyadaddun yanayin ku da bukatunku.MOL Changes.ltd
Tambayoyin da ake yawan yi (FAQ) FAQ
1.Q: Yaya za a adana maganin Tirzepatide foda da aka sake ginawa?
A: Bayan sake gyarawa, Ya kamata a adana maganin Tirzepatide a cikin firiji a 36 ° F zuwa 46 ° F (2°C zuwa 8°C). Kar a daskare maganin. Ya kamata a yi amfani da maganin da aka sake ginawa a ciki 8 hours
2.Q: Can Tirzepatide lyophilized foda za a iya haxa shi da sauran magunguna?
A: A'a, Kada a hada Tirzepatide da wasu magunguna a cikin sirinji iri daya. Ya kamata a gudanar da su daban don guje wa rikice-rikice na miyagun ƙwayoyi.
3.Q: Menene idan na rasa adadin Tirzepatide peptide??
A: Idan kun rasa kashi na Tirzepatide, ɗauki kashi da aka rasa da zarar kun tuna shi, idan a ciki 4 kwanaki bayan kashi da aka rasa. Duk da haka, idan ya kasance fiye da haka 4 kwanaki tun daga kashi na ƙarshe sannan ku tsallake adadin da aka rasa kuma ku ci gaba da jadawalin allurar ku na yau da kullun. Kada a yi allurai biyu a ciki 3 kwanakin juna.
4.Q: Shin akwai wasu illolin Tirzepatide?
A: Kamar kowane magani, Tirzepatid na iya haifar da illa. Illolin gama gari sun haɗa da tashin zuciya, amai, gudawa, da halayen wurin allura. Canje-canje a cikin koda (kamar canjin adadin fitsari), hangen nesa (kamar raguwar hangen nesa), pancreas, ko cutar gallbladder (kamar tashin zuciya/ciwon amai, matsanancin ciwon ciki/ciwon ciki) suna da mummunar illa waɗanda ke buƙatar kulawar likita nan da nan.
5.Q: Za a iya haɗa foda Tirzepatide kafin lokaci?
A: A'a, ana bada shawara don haɗa foda Tirzepatide nan da nan kafin amfani don tabbatar da ƙarfinsa.
6.Q: Me zan yi idan na girgiza vial da gangan?
A: Idan kun girgiza vial da gangan, bari ya zauna na ƴan mintuna don ƙyale kumfa na iska su daidaita. Kada a yi amfani da idan bayani yana kumfa ko ya ƙunshi ɓangarorin bayyane.
7.Q: Za a iya sake amfani da adaftar vial?
A: A'a, adaftar vial don amfani guda ɗaya ne kawai. A zubar da shi da kyau bayan kowane amfani.
8.Q: Yadda za a gudanar da Tirzepatide daidai?
A: Ana ba da shawarar ɗaukar sau ɗaya a mako bisa ga umarnin. Ana iya sha tare da abinci ko a cikin komai a ciki. Ana iya yin allurar cikin cinya, ciki ko babba hannu. Ya kamata a juya wurin allurar kowane lokaci.
Abubuwan Kulawa
Tirzepatide Canje-canje ne na MOL da ake amfani dashi don magance nau'in 2 ciwon sukari da kiba.
Sake daidaitawar Tirzepatide daidai yana da mahimmanci ga tasirin sa.
Bi jagorar mataki-mataki da aka bayar don sake ginawa
Ajiye maganin da aka shirya a cikin firiji kuma amfani da ciki 8 hours.
Kada a hada Tirzepatide da sauran magunguna a cikin sirinji iri daya.
Yadda ake siyan Tirzepatide foda?
Kuna son siyan mafi kyawun Tirzepatide Peptides daga mafi kyawun masu siyar da Tirzepatide foda a kasuwa? Kun zo wurin da ya dace!
MOL Changes.ltd a matsayin masana'antar peptide shine wuri mafi kyau a gare ku don siyan peptide Tirzepatide akan farashi masu gasa daga ƙanana zuwa adadi mai yawa..
Takaitawa
Tirzepatide yana da tasiri sosai a cikin maganin nau'in 2 ciwon sukari da kiba, da kuma koyon yadda za a hada Tirzepatide foda shine muhimmin mataki na kula da lafiyar ku yadda ya kamata. Ta bin matakan sake fasalin da aka bayar a cikin labarin da aka ambata, za ku iya shirya da kyau da kuma shan wannan magani.
Don ƙarin bayani:Tirzepatide
Marubucin wannan labarin:
Dr. Jean Zeng ya sauke karatu daga King's College london Faculty na Kimiyyar Rayuwa & Magani.
Jaridar Kimiyya Mawallafi:
Jami'ar Lorraine, CHRU de Nancy, Brabois Adults Hospital, sashen endocrinology, ciwon sukari da abinci mai gina jiki, rude du Morvan, 54500 Vandoeuvre-lès-Nancy, Faransa
Cibiyar Nazarin Ciwon sukari ta UAB, Jami'ar Alabama a Birmingham, Birmingham, AL, Amurka
3,Qi Liu
Cibiyar Nazarin Zuciya ta Jami'ar Wuhan, Wuhan 430060, Hubei, PR China
Sashen Magunguna, Makarantar Magunguna ta Jami'ar Koc, Istanbul 34010, Turkiyya
5,Francine Mendoza B.S. girma, Pharm.D. Dan takara
Harold Schnitzer Cibiyar Kiwon Lafiyar Ciwon sukari (HSDHC), Jami'ar Kiwon Lafiya da Kimiyya ta Oregon (OHSU), 3270 SW Pavilion Loop, Portland, KO 97239
Babu wata hanya da wannan likita/masanin kimiyya ya yarda ko ba da shawarar siyan, sayarwa, ko amfani da wannan samfurin ga kowane dalili. MOL Changes.ltd bashi da alaƙa ko dangantaka, nuni ko akasin haka, tare da wannan likitan. Manufar kawo wannan likita shine yarda, yarda da yaba cikakken bincike da ayyukan ci gaba da masana kimiyyar da ke aiki akan wannan peptide suka yi.
Maganar Magana
[1]FDA ta Amince da Novel, Magani-Dual-Niyya don Nau'in 2 Ciwon sukari
[2]Matsayin Tirzepatide, Dual GIP da GLP-1 Mai karɓar Agonist, a cikin Gudanar da Nau'in 2 Ciwon sukari: Gwajin asibiti na SURPASS
[3]”Tirzepatide ya rage girman A1C da nauyin jiki a cikin mutane masu nau'in 2 ciwon sukari a cikin kashi biyu 3 gwaji daga shirin SURPASS na Lilly” (Sanarwar manema labarai). Eli Lilly & Kamfanin. 17 Fabrairu 2021. An adana daga asali akan 28 Oktoba 2021. An dawo dasu 28 Oktoba 2021 - ta hanyar PR Newswire
[4]Thomas MK, Nikoienejad A, Bray R, Ku X, Wilson J, Duffin K, da al. (Janairu 2021). "Dual GIP da GLP-1 Mai karɓar Agonist Tirzepatide Yana Inganta Ayyukan Beta-cell da Ƙwararren Insulin a Nau'in 2 Ciwon sukari". Jaridar Clinical Endocrinology da Metabolism. 106 (2): 388-396. doi:10.1210/gangara/dgaa863. PMC 7823251. PMID 33236115.
[5]Daga D, Onishi Y, Norwood P, Haka R, Bray R, Patel H, Rodríguez A (Fabrairu 2022). "Tasirin Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine akan Glycemic Control a Marasa lafiya tare da Nau'in 2 Ciwon sukari: Gwajin Asibiti Bazuwar SURPASS-5". JAMA. 327 (6): 534-545. doi:10.1001/jama.2022.0078. PMC 8826179. PMID 35133415.
[6]”Lilly : Mataki 3 Sakamakon Tirzepatide Yana Nuna Mafi Girma A1C Da Rage Nauyin Jiki A Nau'in 2 Ciwon sukaris". Insider Kasuwanci. Labaran RTT. 19 Oktoba 2021. An adana daga asali akan 28 Oktoba 2021. An dawo dasu 28 Oktoba 2021.
[7]Jastreboff AM, Aron LJ, Ahmad N.N, Wharton S, Koneri L, Alves B, da al. (4 Yuni 2022). "Tirzepatide Sau ɗaya a mako don Maganin Kiba". NEJM. 387 (3): 205-216. doi:10.1056/NEJMoa2206038. PMID 35658024. Farashin S2CID 249385412. An adana daga asali akan 5 Yuni 2022. An dawo dasu 6 Yuni 2022.
Disclaimer: Abubuwan da ke cikin wannan labarin don dalilai na gabaɗaya ne kawai. Wataƙila ba daidai ba ne, cikakke kuma bai kamata a yi la'akari da likita ba, na shari'a, kudi ko wasu shawarwari na sana'a. Duk wani mataki ko yanke shawara da aka ɗauka bisa wannan bayanin alhakin mai amfani ne kaɗai
